Featured Research

from universities, journals, and other organizations

Statin Does Not Appear Helpful For Children With Learning Disabilities Caused By Genetic Disorder

Date:
July 21, 2008
Source:
JAMA and Archives Journals
Summary:
Use of simvastatin by children with neurofibromatosis type 1 (NF1), a genetic disorder that can cause learning disabilities, did not result in improved cognitive function, according to a new study.

Use of simvastatin by children with neurofibromatosis type 1 (NF1), a genetic disorder that can cause learning disabilities, did not result in improved cognitive function, according to a new study.

Related Articles


Characteristics of NF1 (incidence 1:3,000) include skin disorders, problems with small and large movement skills as well as the frequent occurrence of cognitive disabilities, such as visual-spatial skills, nonverbal long-term memory and attention span, according to background information in the article. Some NF1 studies involving mice suggested that use of a statin could improve cognitive deficits.

Lianne C. Krab, M.Sc., of Erasmus MC University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands, and colleagues conducted a randomized trial to study the effect of the statin simvastatin on cognitive function of 62 children with NF1. The participants received simvastatin or placebo treatment once daily for 12 weeks.

After the treatment period, there was no significant difference between the simvastatin and placebo groups on several cognitive measures (determined by testing), including assessing nonverbal long-term memory, assessing attention and prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion, which is thought to be dependent on cerebellar function).

In the secondary outcome measures, the researchers found a significant improvement in the simvastatin group in object assembly scores, which was specifically observed in children with poor baseline performance. Other secondary outcome measures, such as attention fluctuations and a developmental test of visual-motor integration revealed no significant effect of simvastatin treatment.

"The negative outcome of this trial suggests that simvastatin should not be prescribed to ameliorate the cognitive deficits associated with NF1. Further studies to evaluate a longer treatment period and whether the object assembly finding is spurious may be warranted," the authors conclude.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lianne C. Krab; Arja de Goede-Bolder; Femke K. Aarsen; Saskia M. F. Pluijm; Marlies J. Bouman; Jos N. van der Geest; Maarten Lequin; Coriene E. Catsman; Willem Frans M. Arts; Steven A. Kushner; Alcino J. Silva; Chris I. de Zeeuw; Henriette A. Moll; Ype. Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1: A Randomized Controlled Trial. JAMA, 2008;300(3):287-294 [link]

Cite This Page:

JAMA and Archives Journals. "Statin Does Not Appear Helpful For Children With Learning Disabilities Caused By Genetic Disorder." ScienceDaily. ScienceDaily, 21 July 2008. <www.sciencedaily.com/releases/2008/07/080715161933.htm>.
JAMA and Archives Journals. (2008, July 21). Statin Does Not Appear Helpful For Children With Learning Disabilities Caused By Genetic Disorder. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2008/07/080715161933.htm
JAMA and Archives Journals. "Statin Does Not Appear Helpful For Children With Learning Disabilities Caused By Genetic Disorder." ScienceDaily. www.sciencedaily.com/releases/2008/07/080715161933.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins